The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Monoclonal B-cell lymphocytosis: at a crossroad between disease and senescence
Monoclonal B-cell lymphocytosis (MBL) is a preleukemic condition that can evolve into chronic lymphocytic leukemia (CLL). In this video, Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, explains why widespread population screening for MBL is not needed, as most patients with low-count MBL do not go on to develop CLL. The presence of high-count MBL represents a 1-2% increased annual risk of developing CLL, so regular surveillance is necessary in individuals where high-count MBL is detected. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BeiGene: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Lilly/Loxo Oncology: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; MSD: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria, Research Funding.
